Aclaris Therapeutics, Inc. current report, 02 July 2019

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Aclaris Therapeutics, Inc. on July 2, 2019. The filing reports the appointment of Maxine Gowen to the Board of Directors, effective immediately. Dr. Gowen was also appointed to the Audit Committee and Compensation Committee, increasing the membership of each committee from three to four.

Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation arrangements.

Material Changes

The primary material change reported is the expansion of the Board of Directors and its committees. Dr. Gowen, formerly the President and CEO of Trevena, Inc. and a senior executive at GlaxoSmithKline, brings significant biopharmaceutical leadership experience. No material financial changes or transactions exceeding $120,000 involving Dr. Gowen were reported since January 1, 2018.

Guidance, Outlook, and Compensation

The filing details the compensatory arrangements for Dr. Gowen:

  • Initial Grant: A nonqualified stock option to purchase 16,000 shares at an exercise price of $2.34 per share, vesting in 36 equal monthly installments.
  • Annual Retainers: $40,000 for director service, $7,500 for Audit Committee service, and $6,000 for Compensation Committee service.
  • Future Grants: Upon each annual stockholder meeting, Dr. Gowen will receive an option for 11,000 shares (vesting over one year) or an equivalent number of restricted stock units.

The filing includes a Regulation FD disclosure referencing a press release issued on July 3, 2019, regarding this appointment.

Key Facts for Investor Verification

  • Dr. Maxine Gowen's term as a Class II director expires at the 2020 annual meeting of stockholders.
  • The initial stock option grant price of $2.34 reflects the closing price of Aclaris common stock on the grant date.
  • Dr. Gowen currently serves on the boards of Akebia Therapeutics, Inc. and Idera Pharmaceuticals, Inc.
  • The filing explicitly states that the press release and related information are not deemed "filed" for purposes of Section 18 of the Exchange Act.